Search results for:
Ondine continues commercial growth
Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has made significant progress with the commercial roll-out of its novel nasal decolonization technology, Steriwave®, in both Canada and the UK. Steriwave is a simple 5-minute procedure that reduces healthcare-associated infections (HAIs) [...]
King’s College Hospital to run Steriwave pilot
Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King’s College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London’s largest teaching hospitals, will be using [...]
Steriwave receives UAE Regulatory Approval
Ondine receives regulatory approval for Steriwave light-activated antimicrobial technology in the United Arab Emirates Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has received regulatory approval to market Steriwave® nasal decolonization to reduce healthcare-associated infections (HAIs) in patients undergoing [...]
Collaboration advances Steriwave for ICU Market
Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine (AIM) division supports Steriwave ICU use with clinical trials at Royal Columbian Hospital Treatment of patients in intensive care units (ICUs) would significantly expand Ondine’s market opportunity. Infection prevention is a top priority in ICUs as they face higher infection [...]
Ondine secures C$5 million financing
All references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.555041 as at 16:30 (GMT) on 23 September 2024. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has agreed [...]
Steriwave in all British Columbia Health Authorities
Vancouver, British Columbia, Canada - August 23, 2024 Ondine Biomedical Inc. (LON: OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce that Steriwave® nasal decolonization is now being used in all five of British Columbia's health authorities. [...]
Leeds Teaching Hospitals NHS Trust to use Steriwave
Vancouver, British Columbia, Canada - August 6, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, and Iskus Health announce that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave® nasal decolonization technology later this month. Leeds Teaching [...]
Steriwave now available through NHS Supply Chain
Vancouver, British Columbia, Canada - June 21, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, is pleased to announce that its Steriwave® nasal photodisinfection is now available through the NHS Supply Chain, making it significantly easier for NHS [...]
ECDC report shows HAIs are increasing antibiotic use
A third of microorganisms causing healthcare-associated infections were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patients Vancouver, British Columbia, Canada - May 10, 2024 A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore [...]
New study confirms nose is key source of infection
Findings include 86% of surgical site infections caused by bacteria from the patients’ own nose, skin, or gut and nearly 60% of infections are resistant to antibiotics Vancouver, British Columbia, Canada - April 25, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company [...]
For Media Information
Simon Vane Percy
Amanda Bernard
